Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGruppo Italiano Malattie EMatologiche dell'Adulto
About this trial
This multicenter, prospective and retrospective observational study aims to evaluate the use and efficacy of new drugs or their combinations in real-life in a population of adult AML patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged 18 years or older
AML diagnosis according to the ELN guidelines, excluding M3
Signed Informed consent, if applicable
patients affected by FLT3-mutated AML treated with gilteritinib.
Disqualifiers
None
Trial population
population of adult AML patients treated at Italian GIMEMA centers
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
New therapies efficacy in terms of Overall survival
evaluation of the efficacy of the new therapies or their combinations in the real-life for AML patients in terms of Overall Survival
Time frame
at 24 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov